Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Oncosil Medical stock price, quote, forecast and news

OSL.AX
AU000000OSL3
A1WZU4

Price

0.01 AUD
Today +/-
+0 AUD
Today %
+0 %
P

Oncosil Medical stock price

AUD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Oncosil Medical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Oncosil Medical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Oncosil Medical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Oncosil Medical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Oncosil Medical Stock Price History

DateOncosil Medical Price
8/23/20240.01 AUD
8/22/20240.01 AUD
8/21/20240.01 AUD
8/20/20240.01 AUD
8/19/20240.01 AUD
8/16/20240.01 AUD
8/15/20240.01 AUD
8/14/20240.01 AUD
8/13/20240.01 AUD
8/12/20240.01 AUD
8/9/20240.01 AUD
8/8/20240.01 AUD
8/7/20240.01 AUD
8/6/20240.01 AUD
8/5/20240.01 AUD
8/2/20240.01 AUD
8/1/20240.01 AUD
7/31/20240.01 AUD
7/30/20240.01 AUD
7/29/20240.01 AUD

Oncosil Medical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oncosil Medical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oncosil Medical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oncosil Medical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oncosil Medical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oncosil Medical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oncosil Medical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oncosil Medical’s growth potential.

Oncosil Medical Revenue, EBIT and net profit per share

DateOncosil Medical RevenueOncosil Medical EBITOncosil Medical Net Income
2027e60.5 M AUD0 AUD0 AUD
2026e34.6 M AUD-9.32 M AUD-45.1 M AUD
2025e14 M AUD11.72 M AUD38.22 M AUD
2024e4.87 M AUD-12.78 M AUD-41.54 M AUD
2023430,280 AUD-11.27 M AUD-11.34 M AUD
20221.07 M AUD-10.57 M AUD-10.73 M AUD
20211.38 M AUD-10.46 M AUD-10.43 M AUD
20202.87 M AUD-4.34 M AUD-4.26 M AUD
20193.83 M AUD-8.58 M AUD-8.57 M AUD
20184.59 M AUD-8.5 M AUD-8.54 M AUD
20173.76 M AUD-7.05 M AUD-7.02 M AUD
20164.1 M AUD-4.77 M AUD-4.77 M AUD
20153.03 M AUD-2.63 M AUD-2.88 M AUD
2014250,000 AUD-4.44 M AUD-4.22 M AUD
2013100,000 AUD-890,000 AUD-880,000 AUD
2012140,000 AUD-280,000 AUD-430,000 AUD
2011110,000 AUD-390,000 AUD-1.46 M AUD
20102.11 M AUD40,000 AUD-1.71 M AUD
20092.37 M AUD-450,000 AUD-440,000 AUD
20082.19 M AUD-2.95 M AUD-2.77 M AUD
20071.85 M AUD-1.67 M AUD-1.67 M AUD
20061.54 M AUD-130,000 AUD-130,000 AUD
200510,000 AUD-30,000 AUD-30,000 AUD
20040 AUD0 AUD0 AUD

Oncosil Medical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M AUD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k AUD)EBIT (M AUD)EBIT MARGIN (%)NET INCOME (M AUD)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
001122200003434321104133460
----100.00-------33.33-25.0033.33-25.00-33.33-50.00---225.00161.5476.47
----50.00-------------------
00001,00000000000000000-1,0000000
000-1-200000-4-2-4-7-8-8-4-10-10-11-1211-90
----100.00-100.00-------66.67-100.00-233.33-200.00-266.67-200.00-1,000.00-1,000.00--300.0084.62-26.47-
000-1-20-1-100-4-2-4-7-8-8-4-10-10-11-4138-450
----100.00-------50.00100.0075.0014.29--50.00150.00-10.00272.73-192.68-218.42-
0.010.020.040.040.060.060.060.080.10.130.490.360.40.490.530.650.821.081.061.20000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Oncosil Medical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Oncosil Medical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M AUD)RECEIVABLES (k AUD)OTHER REC. (M AUD)INVENTORIES (M AUD)OTHER CURRENT LIAB. (M AUD)CURRENT ASSETS (M AUD)TANGIBLE ASSETS (M AUD)LONG-T. INVEST. (k AUD)LONG-T. REC. (k AUD)INTANGIBLE ASSETS (M AUD)GOODWILL (M AUD)OTHER NON-CURRENT ASSETS (M AUD)NON-CURRENT ASSETS (M AUD)TOTAL ASSETS (M AUD)LIABILITIESCOMMON STOCK (M AUD)ADDITIONAL PAID-IN CAPITAL (M AUD)RETAINED EARNINGS (M AUD)OTHER EQUITY (k AUD)UNREAL. GAINS/LOSSES (M AUD)EQUITY (M AUD)LIABILITIES (M AUD)PROVISIONS (k AUD)OTHER SHORT-TERM LIAB. (k AUD)SHORT-TERM DEBTS (k AUD)LONG-TERM DEBT PORTION (k AUD)SHORT-TERM REC. (M AUD)LONG-T. LIAB. (k AUD)DEFERRED TAXES (k AUD)OTHER LIAB. (k AUD)LONG-T. LIABILITIES (M AUD)DEBT (M AUD)TOTAL CAPITAL (M AUD)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
0.30.892.821.91.751.41.552.872.493.577.09013.04815.217.692112.2411.289.39
00320400530500330000000000028.6916.561.25
000.290.210000.110000000001.150.891.22
00000000000000000000
00.030.010.030.020.10.040.050.030.022.531.160.140.160.110.10.120.20.560.56
0.30.923.442.542.321.923.032.523.599.621.1613.188.1615.317.7921.1213.6212.7411.23
001.080.80.520.260.140000.0200.090.120.090.060.140.530.320.24
030000000000000000000
000000000000000007660125
001.821.821.511.140002.652.65000000000
001.841.841.841.840.90000000000000
00000000000000000000
00.034.744.463.873.241.04002.652.6700.090.120.090.060.140.610.380.36
0.30.958.1876.175.242.963.032.526.2412.291.1613.278.2815.47.8521.2514.2313.1311.6
0.30.935.576.378.518.638.79.719.7113.8923.79035.6936.6452.2652.2670.1470.479.9186.51
00000000000000000000
0-0.03-0.11-1.69-4.42-4.35-6.12-6.79-7.23-7.84-11.630-20.88-26.51-34.1-41.58-48.07-58.65-68.78-76.66
0000000000000000-162.39-52.9434.4334.77
00000000000000000000
0.30.95.464.684.094.282.582.922.486.0512.16014.8110.1318.1510.6821.911.711.169.88
00.040.510.650.740.180.080.10.010.050.0400.971.521.60.771.361.230.930.96
00000001030140800118.43145.79128.73225.6484.61510.49342.92163.9
010640570600300260000000000208.4232.24328.49298.86
000000000000000026.56000
002101801500000000000083.38163.24165.38146.25
00.051.361.41.490.480.340.110.040.190.1201.091.671.730.992.162.131.771.57
004001900000000000000321.13138.8424.56
00550560590480300000000000000
004101900000000000000000
001.360.940.590.480.0300000000000.320.140.02
00.052.722.342.080.960.370.110.040.190.1201.091.671.730.992.162.451.911.59
0.30.958.187.026.175.242.953.032.526.2412.28015.911.819.8811.6724.0614.1513.0711.47
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Oncosil Medical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Oncosil Medical's financial health and stability.

Assets

Oncosil Medical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Oncosil Medical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Oncosil Medical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Oncosil Medical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M AUD)DEPRECIATION (M AUD)DEFERRED TAXES (M AUD)CHANGES IN WORKING CAPITAL (M AUD)NON-CASH ITEM (M AUD)PAID INTEREST (M AUD)PAID TAXES (M AUD)NET CASH FLOW FROM OPERATING ACTIVITIES (M AUD)CAPITAL EXPENDITURES (M AUD)CASH FLOW FROM INVESTING ACTIVITIES (M AUD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M AUD)INTEREST INCOME AND EXPENSES (M AUD)NET DEBT CHANGE (M AUD)NET CHANGE IN EQUITY (M AUD)CASH FLOW FROM FINANCING ACTIVITIES (M AUD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (AUD)TOTAL DIVIDENDS PAID (M AUD)NET CHANGE IN CASH FLOW (M AUD)FREE CASH FLOW (M AUD)SHARE-BASED COMPENSATION (M AUD)
2004null2005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000-10-100
000000000000000000000
000000000000000000000
000000000000312343200
000000000000000000000
000000000000000000000
000000000000000000000
0000-1-200000-60-4-6-8-7-4-8-10-11
000000000000000000000
00000000000-4003000000
00000000000-4003000000
000000000000000000000
000000000000000000000
0001020010110012016019099
000102001019011015017099
----------------1.00--1.00---
000000000000000000000
0001-2-200000-7-30-10-4-194-20-11-14
00-0.02-0.07-1.59-2.22-0.180.12-0.32-0.31-0.57-6.39-0.22-4.63-6.16-8.41-7.52-4.48-8.87-10.12-11.37
000000000000000000000

Oncosil Medical stock margins

The Oncosil Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncosil Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncosil Medical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oncosil Medical's sales revenue. A higher gross margin percentage indicates that the Oncosil Medical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oncosil Medical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oncosil Medical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oncosil Medical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oncosil Medical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oncosil Medical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oncosil Medical Margin History

Oncosil Medical Gross marginOncosil Medical Profit marginOncosil Medical EBIT marginOncosil Medical Profit margin
2027e-269.24 %0 %0 %
2026e-269.24 %-26.92 %-130.32 %
2025e-269.24 %83.71 %273.01 %
2024e-269.24 %-262.56 %-853.4 %
2023-269.24 %-2,619.9 %-2,636.17 %
20229.41 %-984.39 %-999.21 %
202130.4 %-757.48 %-755.61 %
2020-269.24 %-151.32 %-148.57 %
2019-269.24 %-224.05 %-223.66 %
2018-269.24 %-185.01 %-185.95 %
2017-269.24 %-187.82 %-186.81 %
2016-269.24 %-116.25 %-116.22 %
2015-269.24 %-86.87 %-95.08 %
2014-269.24 %-1,776 %-1,688 %
2013-269.24 %-890 %-880 %
2012-269.24 %-200 %-307.14 %
2011-269.24 %-354.55 %-1,327.27 %
201034.12 %1.9 %-81.04 %
200938.4 %-18.99 %-18.57 %
200850.23 %-134.7 %-126.48 %
200748.11 %-90.27 %-90.27 %
200662.34 %-8.44 %-8.44 %
2005-269.24 %-300 %-300 %
2004-269.24 %0 %0 %

Oncosil Medical Stock Sales Revenue, EBIT, Earnings per Share

The Oncosil Medical earnings per share therefore indicates how much revenue Oncosil Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oncosil Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oncosil Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oncosil Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oncosil Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Oncosil Medical Revenue, EBIT and net profit per share

DateOncosil Medical Sales per ShareOncosil Medical EBIT per shareOncosil Medical Earnings per Share
2027e0.02 AUD0 AUD0 AUD
2026e0.01 AUD0 AUD-0.01 AUD
2025e0 AUD0 AUD0.01 AUD
2024e0 AUD0 AUD-0.01 AUD
20230 AUD-0.01 AUD-0.01 AUD
20220 AUD-0.01 AUD-0.01 AUD
20210 AUD-0.01 AUD-0.01 AUD
20200 AUD-0.01 AUD-0.01 AUD
20190.01 AUD-0.01 AUD-0.01 AUD
20180.01 AUD-0.02 AUD-0.02 AUD
20170.01 AUD-0.01 AUD-0.01 AUD
20160.01 AUD-0.01 AUD-0.01 AUD
20150.01 AUD-0.01 AUD-0.01 AUD
20140 AUD-0.01 AUD-0.01 AUD
20130 AUD-0.01 AUD-0.01 AUD
20120 AUD-0 AUD-0 AUD
20110 AUD-0 AUD-0.02 AUD
20100.03 AUD0 AUD-0.03 AUD
20090.04 AUD-0.01 AUD-0.01 AUD
20080.03 AUD-0.05 AUD-0.04 AUD
20070.04 AUD-0.04 AUD-0.04 AUD
20060.04 AUD-0 AUD-0 AUD
20050 AUD-0 AUD-0 AUD
20040 AUD0 AUD0 AUD

Oncosil Medical business model

Oncosil Medical Ltd is an Australian company specializing in the development and distribution of innovative medical products for the treatment of cancer. The company was founded in 2005 and is based in Sydney. The business model of Oncosil Medical is based on research, development, and marketing of products specifically tailored to the needs of cancer patients. The company focuses on developing medical products that aim to improve the effectiveness of radiation therapy and chemotherapy. The core product of Oncosil Medical is the Oncosil implant. It is a small, implantable catheter containing tiny radioactive silicon particles. The implant is directly inserted into the tumor and releases controlled radiation to specifically destroy the tumor. The Oncosil implant is a promising and innovative new treatment option for many cancer patients. It is particularly suitable for patients with locally advanced pancreatic cancer, which is especially difficult to treat. Studies have shown that the Oncosil implant can significantly improve patients' survival rate. Oncosil Medical also provides other products, such as the Microsil transponder. The Microsil transponder is a small implant used in radiation therapy to make the irradiation of the tumor more effective. The transponder is directly inserted into the tumor, allowing medical professionals to precisely target the radiation to the tumor. In addition to developing and marketing innovative medical products, Oncosil Medical also has a research and development department. The company is constantly searching for new cancer treatment methods and works closely with scientists and researchers to develop new technologies. Oncosil Medical operates in several areas. In addition to developing and marketing medical products, the company also offers a training and education program for doctors and medical personnel. The program ensures that all users of Oncosil Medical's products have the necessary skills and knowledge to use the products safely and effectively. The company also has its own regulatory affairs department, which deals with the application for approvals for new products and procedures. This department works closely with authorities and regulatory agencies to ensure that all products from Oncosil Medical comply with applicable regulations and standards. Overall, Oncosil Medical is an innovative and emerging company specializing in the development and marketing of medical products for cancer treatment. With its highly skilled team of scientists, doctors, and qualified professionals, the company stays up to date with the latest research and technology to ensure that its products are always state-of-the-art and provide customers with the best possible treatment option. Oncosil Medical is one of the most popular companies on Eulerpool.com.

Oncosil Medical SWOT Analysis

Strengths

Oncosil Medical Ltd has a proprietary medical technology that has shown potential in treating various types of solid tumors.

The company has a strong intellectual property portfolio, including patents and trademarks, which provides a competitive advantage.

Oncosil has a dedicated and experienced team of researchers and medical professionals who are committed to advancing the field of oncology.

Weaknesses

The company is currently in the early stages of development and has not yet commercialized its technology, which creates financial uncertainties.

Oncosil Medical Ltd heavily relies on external funding to support its research and development efforts, making it vulnerable to market fluctuations.

The regulatory approval process for medical devices and treatments can be lengthy and costly, posing potential delays and obstacles for the company.

Opportunities

The global oncology market is experiencing significant growth, driven by increasing cancer rates and advancements in medical technology, presenting a favorable market environment for Oncosil.

Partnerships and collaborations with established pharmaceutical companies can provide access to additional resources and accelerate the commercialization process.

Expansion into international markets, particularly regions with high cancer prevalence, offers the potential for increased revenue and market share.

Threats

Competition in the oncology space is intense, with numerous established companies and startups vying for market share.

Changes in healthcare regulations and reimbursement policies may impact the adoption and pricing of Oncosil's technology.

Failure to meet clinical trial endpoints or demonstrate the efficacy and safety of its products could hinder regulatory approvals and market acceptance.

Oncosil Medical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Oncosil Medical historical P/E ratio, EBIT, and P/S ratio.

Oncosil Medical shares outstanding

The number of shares was Oncosil Medical in 2023 — This indicates how many shares 1.196 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Oncosil Medical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Oncosil Medical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Oncosil Medical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Oncosil Medical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Oncosil Medical.

Oncosil Medical list of shareholders

%
Name
Stocks
Change
Date
3.14 % Cameron (Sarah)118,661,21546,0008/23/2023
1.26 % Alua Capital Pty. Ltd.47,653,84735,000,0008/23/2023
1.22 % Bannaby Investments Pty. Ltd.46,000,00035,000,0008/23/2023
1.18 % Peter Kyros Pty Ltd44,656,78024,156,7808/23/2023
0.90 % Myconsulting Pty. Ltd.34,000,00034,000,0008/23/2023
0.87 % Harris (Gregory Joseph)32,999,93017,069,2338/23/2023
0.85 % Newfound Investments Pty Ltd32,307,69432,307,6948/23/2023
0.77 % Sunset Capital Management Pty. Ltd.29,000,00021,000,0008/23/2023
0.72 % Netwealth Investments Ltd.27,228,094698,4398/23/2023
0.68 % Henderson Family25,845,9652,725,7148/23/2023
1
2
3

Oncosil Medical Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
EyePoint Pharmaceuticals Stock
EyePoint Pharmaceuticals
SupplierCustomer0,26-0,30-0,040,13-0,40-0,69
1

Most common questions regarding Oncosil Medical

What values and corporate philosophy does Oncosil Medical represent?

Oncosil Medical Ltd is a leading medical technology company dedicated to revolutionizing cancer treatment. The company's core values include innovation, excellence, and patient-centricity. Oncosil Medical is driven by a corporate philosophy that emphasizes cutting-edge research, strategic partnerships, and delivering effective and safe medical solutions to patients worldwide. By leveraging its expertise in radiotherapy and brachytherapy, Oncosil Medical aims to improve the quality of life for cancer patients and provide them with new hope. With a commitment to advancing cancer therapies, Oncosil Medical Ltd stands as a reliable and compassionate ally in the fight against cancer.

In which countries and regions is Oncosil Medical primarily present?

Oncosil Medical Ltd is primarily present in Australia.

What significant milestones has the company Oncosil Medical achieved?

Oncosil Medical Ltd has achieved several significant milestones. Firstly, the company successfully completed its pivotal global clinical trial for the use of OncoSil™ as a treatment for pancreatic cancer. This trial demonstrated positive results and paved the way for regulatory approvals. Secondly, Oncosil Medical Ltd received CE Mark approval in Europe, allowing for the commercialization of OncoSil™ in the European Union. Furthermore, the company secured regulatory approval from the Australian Therapeutic Goods Administration. These achievements mark Oncosil Medical Ltd's progress in developing innovative solutions for cancer treatment, positioning the company as a leader in the field.

What is the history and background of the company Oncosil Medical?

Oncosil Medical Ltd is an Australian-based medical technology company specializing in the development and commercialization of innovative products for the treatment of cancer. Established in 1995, Oncosil Medical Ltd has since focused on enhancing radiotherapy treatments through its unique targeted radiation therapy approach. The company's flagship product, the OncoSil™ device, is designed to deliver localized radiation directly to tumors, providing a more effective and targeted treatment option for patients. With a strong commitment to improving patient outcomes, Oncosil Medical Ltd continues to innovate and expand its product pipeline, aiming to revolutionize cancer treatment worldwide.

Who are the main competitors of Oncosil Medical in the market?

The main competitors of Oncosil Medical Ltd in the market include medical companies such as Varian Medical Systems, Isoray Inc., and Monarch Medical Technologies.

In which industries is Oncosil Medical primarily active?

Oncosil Medical Ltd is primarily active in the healthcare industry.

What is the business model of Oncosil Medical?

The business model of Oncosil Medical Ltd focuses on developing and commercializing innovative medical devices for the treatment of various cancers. The company's flagship product, Oncosil™, is a minimally invasive implantable device that delivers a targeted dose of radiation directly to tumor sites. This unique approach aims to improve cancer treatment outcomes by enhancing the efficacy of radiation therapy while minimizing side effects. Oncosil Medical Ltd also collaborates with leading research institutions and medical centers to further advance the understanding and applications of its technology. By providing a targeted and precise treatment option, Oncosil Medical Ltd aims to improve the lives of cancer patients worldwide.

What is the P/E ratio of Oncosil Medical 2024?

The Oncosil Medical P/E ratio is -0.3.

What is the P/S ratio of Oncosil Medical 2024?

The Oncosil Medical P/S ratio is 2.58.

What is the AlleAktien quality score of Oncosil Medical?

The AlleAktien quality score for Oncosil Medical is 6/10.

What is the revenue of Oncosil Medical 2024?

The expected Oncosil Medical revenue is 4.87 M AUD.

How high is the profit of Oncosil Medical 2024?

The expected Oncosil Medical profit is -41.54 M AUD.

What is the business model of Oncosil Medical

Oncosil Medical Ltd is an Australian-based medical company specializing in the development and marketing of innovative medical devices for tumor radiation therapy. The company aims to help cancer patients worldwide achieve a better quality of life.

What is the Oncosil Medical dividend?

Oncosil Medical pays a dividend of 0 AUD distributed over payouts per year.

How often does Oncosil Medical pay dividends?

The dividend cannot currently be calculated for Oncosil Medical or the company does not pay out a dividend.

What is the Oncosil Medical ISIN?

The ISIN of Oncosil Medical is AU000000OSL3.

What is the Oncosil Medical WKN?

The WKN of Oncosil Medical is A1WZU4.

What is the Oncosil Medical ticker?

The ticker of Oncosil Medical is OSL.AX.

How much dividend does Oncosil Medical pay?

Over the past 12 months, Oncosil Medical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncosil Medical is expected to pay a dividend of 0 AUD.

What is the dividend yield of Oncosil Medical?

The current dividend yield of Oncosil Medical is .

When does Oncosil Medical pay dividends?

Oncosil Medical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncosil Medical?

Oncosil Medical paid dividends every year for the past 0 years.

What is the dividend of Oncosil Medical?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncosil Medical located?

Oncosil Medical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncosil Medical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncosil Medical from 8/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Oncosil Medical pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Oncosil Medical in the year 2023?

In the year 2023, Oncosil Medical distributed 0 AUD as dividends.

In which currency does Oncosil Medical pay out the dividend?

The dividends of Oncosil Medical are distributed in AUD.

All fundamentals about Oncosil Medical

Our stock analysis for Oncosil Medical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncosil Medical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.